Copy to clipboard 
Ortho Development received 510(k) clearance to market the Trivicta Hip System. The triple-taper femoral stem facilitates an optimal fit within the canal for a diverse range of patient anatomies.
Limited U.S. launch will commence in 2Q24, with full commercial release to follow.
Designed for initial and long-term stability, Trivicta boasts a triple-tapered geometry in three separate planes and incorporates two coatings. Sintered beads provide initial stability and allow ingrowth for long-term stability, while Hydroxyapatite promotes biological fixation. Additionally, extraction and compaction broaching are integrated in one broach to preserve bone while ensuring optimal fit.
“Trivicta expands our extensive primary hip portfolio and incorporates our philosophy of evolutionary innovation. The system is designed to be versatile enough to address the vast needs of patients and surgeons, accommodating both muscle-sparing and traditional surgical approaches,” said Brent Bartholomew, President & CEO of Ortho Development.
Source: Ortho Development Corporation
